Considering the reported contribution of GILZ in the control of T-cell responses and the potential of this protein as an immune checkpoint in cancer settings, these results need to be considered for optimal targeting of GILZ in therapeutic strategies. This evidence concerns the gene TSC22D3 and cancer.